Johnson & Johnson Stock (JNJ) Moved Down by 3.29% on Mar 5: Drivers Behind the Movement

Johnson & Johnson (JNJ) moved down by 3.29%. The Pharmaceuticals & Medical Research sector is down by 2.91%. The company underperformed the industry. Top 3 stocks by trading volume in the sector: Eli Lilly and Co (LLY) down 2.88%; Johnson & Johnson (JNJ) down 3.29%; AbbVie Inc (ABBV) down 2.87%.

What is driving Johnson & Johnson (JNJ)’s stock price down today?

Shares of Johnson & Johnson experienced a notable downward movement today, reflecting a confluence of factors influencing investor sentiment. A significant contributor to this decline appears to be heightened competitive pressure in a key therapeutic area. United Therapeutics announced positive Phase 3 clinical trial results for ralinepag, a drug candidate poised to challenge Johnson & Johnson's Uptravi in the pulmonary arterial hypertension market. United Therapeutics' drug demonstrated a substantial reduction in the risk of clinical worsening and, with its once-daily dosing potential, could directly compete with Johnson & Johnson's established twice-daily product.

Adding to the negative sentiment are ongoing concerns surrounding Johnson & Johnson's talc litigation. While not a new development, these legal actions continue to pose headline and reserve risks for the company, and past rulings allowing expert testimony linking products to health issues have previously impacted the stock.

Further contributing to the downward pressure were recent adjustments in institutional portfolios and insider activity. Burgundy Asset Management Ltd. reduced its holdings in Johnson & Johnson by 2.0% in the third quarter. Additionally, several company executives, including EVP Vanessa Broadhurst and Timothy Schmid, engaged in share sales in mid-February, signaling a decrease in their direct ownership of company stock. Algorithmic trading frameworks also detected elevated downside risk and a prevailing neutral sentiment for Johnson & Johnson today, suggesting technical weakness.

Despite these pressures, Johnson & Johnson had previously reported strong fourth-quarter 2025 earnings and provided positive guidance for 2026. However, even those earlier announcements saw the stock decline due to concerns about increased competition and the impact of a drug pricing agreement. More recently, the company also received FDA Fast Track designation for nipocalimab in systemic lupus erythematosus, a generally positive development, but its potential impact is likely longer-term. The current market reaction indicates that immediate competitive threats and persistent legal risks are outweighing the longer-term positive developments and past financial performance.

Technical Analysis of Johnson & Johnson (JNJ)

Technically, Johnson & Johnson (JNJ) shows a MACD (12,26,9) value of [6.68], indicating a neutral signal. The RSI at 63.79 suggests neutral condition and the Williams %R at -53.28 suggests oversold condition. Please monitor closely.

Fundamental Analysis of Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ) is in the Pharmaceuticals & Medical Research industry. Its latest annual revenue is $94.19B, ranking 3 in the industry. The net profit is $26.80B, ranking 1 in the industry. Company Profile

Over the past month, multiple analysts have rated the company as Buy, with an average price target of $233.26, a high of $265.00, and a low of $170.00.

More details about Johnson & Johnson (JNJ)

Company Specific Risks:

• A Maryland jury recently awarded $1.5 billion, and a Philadelphia jury found J&J liable in a talc ovarian cancer lawsuit, intensifying ongoing litigation and highlighting substantial, unresolved financial and legal exposure.
• Repeated rejections of Johnson & Johnson's bankruptcy attempts to settle talcum powder claims, with the latest $8.9 billion plan rejected in April 2025 and a third bankruptcy attempt dismissed, indicate a protracted and costly resolution process for tens of thousands of pending lawsuits.
• Institutional analysts express concern over "lingering litigation risks" as a primary constraint on a more bullish stance, contributing to limited upside potential for the stock despite positive pipeline developments.
• A recent lawsuit filed by Bayer against J&J's Janssen unit regarding prostate cancer drug marketing claims introduces new and uncertain litigation risks, adding to the company's legal challenges.